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previr. The patient presented with a large erosion of the
lower vermilion with honey-colored and hemorrhagic
crusting (A) and ill-defined erythematous plaques with
overlying tense bullae on the dorsolateral hands (B).INTRODUCTION
Recently there has been a rapid evolution in the
treatment of hepatitis C heralded by development
of the direct-acting antiviral agents, which target
specific aspects of the hepatitis C virus viral cycle.
These agents have shown improved sustained
virologic response rates compared with traditional
therapy with combined pegylated interferon and
ribavirin.1,2 Simeprevir, a direct-acting antiviral
agent, is a second-generation viral protease inhib-
itor that has proven highly effective and safe for
the treatment of genotype I chronic hepatitis C and
was approved by the US Food and Drug
Administration in November 2013.2 In clinical
trials, simeprevir was initially used in combination
with ribavirin and pegylated interferon alfa but
recently has been paired with another newly
emerged targeted antiviral, sofosbuvir. Sofosbuvir
is a nucleotide analog inhibitor of hepatitis C viral
polymerase.1 In a recent randomized trial that
compared patients on combined simeprevir/sofos-
buvir with or without ribavirin, a rash was seen in
13.6% of the patients on the combined therapy
without ribavirin.3 To date, there are few clear
descriptions of this rash in the medical literature.
We present a case of a photo-induced drug
eruption in a patient on simeprevir and sofosbuvir
for hepatitis C.CASE REPORT
A 65 year-old white woman, 1 year status poste
liver transplant and currently undergoing treatment
for hepatitis C, was referred to the dermatologythe School of Medicinea and the Department of Dermato-
y,b University of Utah.
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odcock@hsc.utah.edu.clinic by her primary care physician for evaluation
of painful, clear, fluid-filled blisters on the lower
lip, right cheek, and dorsal hands after not
responding to 2 courses of acyclovir. Two weeks
before onset of this eruption, she was started on
combined simeprevir/sofosbuvir regimen for hep-
atitis C infection. Her other medications included
tacrolimus and everolimus for transplantJAAD Case Reports 2016;2:224-6.
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Fig 2. Histopathology shows spongiotic dermatitis with marked papillary dermal edema and
a perivascular infiltrate of composed of lymphocytes, few neutrophils, and rare eosinophils.
(A and B, Hematoxylin-eosin stain; original magnifications: A, 3100 and B, 3200.)
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Eyre, Secrest, and Woodcock 225immunosuppression, levothyroxine, insulin, alend-
ronate, amlodipine, omeprazole, simvastatin, and
calcium with vitamin D, none of which had been
started within the past 6 months. She had no
history of medication allergies and denied any
similar rashes in the past. The patient denied
prolonged sun exposure before onset of the
eruption.
When examined in the dermatology clinic,
she presented with a large erosion of the lower
vermilion with honey-colored and hemorrhagic
crusting (Fig 1, A). There were also ill-defined
erythematous plaques with overlying tense bullae
on the dorsolateral hands, right more so than left
(Fig 1, B). Wound culture of the lip found normal
skin flora. Herpes simplex virus polymerase chain
reaction testing of a bulla on the right hand was
negative. A punch biopsy of the right dorsal hand
found spongiotic dermatitis with marked papillary
dermal edema and a perivascular infiltrate of
composed of lymphocytes, few neutrophils, and
rare eosinophils (Fig 2, A and B). There was no
evidence of herpetic infection on pathology. The
clinical and histologic features were consistent with a
drug eruption presumed secondary to treatment for
her hepatitis C. At the time of diagnosis, the patient
was almost halfway through her 12-week course of
simeprevir/sofosbuvir and elected to complete the
antiviral treatment. Therefore, she was prescribed
triamcinolone 0.1% cream for her hands and
desonide 0.05% cream for her lips. The rash
significantly improved with topical steroids within
2 weeks and resolved on completion of the antiviral
medications.DISCUSSION
Photo-induced drug eruptions are responsible for
only 8% of reported cutaneous adverse events from
medications, and are classified into 2 categories,
phototoxic or photoallergic, based on their
pathogenesis. Photoallergic drug eruptions in
contrast to phototoxic are immune-mediated and
do not occur in all individuals exposed to the
medication and solar radiation. Photoallergic
reactions are usually eczematous clinically and
have histology demonstrating spongiosis and
vesiculation of the epidermis with dermal
perivascular inflammation. Phototoxic eruptions
occur much more commonly and often present as
exaggerated sunburn with pathology exhibiting
apoptotic keratinocytes and a dermal infiltrate of
neutrophils and lymphocytes. It can be difficult to
differentiate between phototoxic and photoallergic
eruptions, which can be aided by photopatch
testing, although this often does not change the
management in these cases.4
The eczematous appearance, distribution, and
histology of the eruption in our patient are consistent
with a photo-induced drug eruption. Our patient did
not recall significant sun exposure, but the ultraviolet
light received through a windshield while driving
would be sufficient to cause this eruption and explain
the involvement of the dorsolateral hands. A recent
publication by Simpson et al5 describes 2 patients
presenting with a photo-distributed eruption after
starting simeprevir/sofosbuvir for hepatitis C, which
showed a lichenoid pattern on histology.5 We
considered these cases to be photoallergic eruptions,
but the lichenoid pattern on pathology, burning
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hyperpigmentation seen in one of the cases are
more consistent with a phototoxic mechanism.5,6
Pathology in our case would favor a photoallergic
reaction given the lack of apoptotic keratinocytes,
but further photoprovocation testing is necessary to
clearly delineate this mechanism.
In phase III clinical trials comparing simeprevir
plus peginterferon and ribavirin with placebo plus
peginterferon and ribavirin, there were similar rates
of rash between the 2 groups. However, photosen-
sitivity was seen in the simeprevir group at rates of
1.6% to 4% compared with less than 1% in the
placebo group.7 In the phase III clinical trials for
sofosbuvir, rates of rash were also similar in the
treatment groups compared with placebo with no
reports of photosensitivity.8-10 A recent trial of
combined simeprevir/sofosbuvir with or without
ribavirin demonstrated rash in 13.6% of the group
without ribavirin and overall rate of photosensitivity
of 5%.3 Simpson et al5 speculate that simeprevir is the
causative agent of the eruptions in their report given
the higher incidence of photosensitivity with
simeprevir compared with placebo clinical trials,
which has not been described with sofosbuvir.7 We
agree that simeprevir is the likely causative agent in
our patient given the photo-distributed nature.5
A recent trial found that combined simeprevir/
sofosbuvirwasmore effective in achieving a sustained
virologic response and was better tolerated than
combined ribavirin, peginterferon, and sofosbuvir.1
The introduction of these 2 drugs has revolutionized
the treatment of hepatitis C and are now the preferredtherapy.7 Because of their success and predicted
future use, a greater understanding of their dermato-
logic adverse events is necessary.
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